News | November 09, 2025
Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Subscribe To Our Newsletter & Stay Updated
